Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Qiagen ( (QGEN) ).
Qiagen N.V. has announced a significant update regarding its voting rights, as informed by the Netherlands Authority for the Financial Markets (AFM). BlackRock, Inc. has disclosed its holdings in Qiagen, which include a substantial capital interest and voting rights, indicating a strong influence in the company’s governance. This announcement highlights BlackRock’s strategic positioning and potential impact on Qiagen’s future decisions, reflecting the dynamic nature of stakeholder influence in the biotechnology sector.
The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company focuses on enabling customers to gain valuable insights from biological samples and is listed on multiple stock exchanges, including Frankfurt and NYSE.
Average Trading Volume: 1,456,737
Technical Sentiment Signal: Buy
Current Market Cap: $11.09B
See more data about QGEN stock on TipRanks’ Stock Analysis page.